drug

SRP-1005

1 story · latest Aug 5, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Sarepta Therapeutics, Inc.

Timeline

Sarepta names Michael Severino CEO, reports Q2 2026 results and pipeline updates

Aug 5Quarterly updateSarepta Therapeutics, Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.